Product Description
a triple reuptake inhibitor of dopamine, norepinephrine and serotonin (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244379/)
Mechanisms of Action: DRI Inhibitor,SRI Inhibitor,NRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nestle
Company Location: VEVEY V8
Company CEO:
Additional Commercial Interests: Enterome
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Depressive Disorder, Major
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| SNRIs | P3 |
Completed |
Depressive Disorder, Major |
2013-02-01 |
2019-03-19 |
Treatments |